Targeting ALK in neuroblastomaâ€”preclinical and clin

Nature Reviews Clinical Oncology

9, 391-399

DOI: 10.1038/nrclinonc.2012.72

Citation Report

#	Article	IF	Citations
1	Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochemical Journal, 2012, 448, 213-220.	1.7	75
2	Towards a turning point of neuroblastoma therapy. Cancer Letters, 2012, 326, 128-134.	3.2	29
3	Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma. Pediatric Blood and Cancer, 2013, 60, 1636-1641.	0.8	27
4	Targeting developmental pathways in children with cancer: what price success?. Lancet Oncology, The, 2013, 14, e70-e78.	5.1	30
5	ALK amplification and protein expression predict inferior prognosis in neuroblastomas. Experimental and Molecular Pathology, 2013, 95, 124-130.	0.9	39
6	At the frontier of progress for paediatric oncology: the neuroblastoma paradigm. British Medical Bulletin, 2013, 108, 173-188.	2.7	13
7	Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nature Reviews Cancer, 2013, 13, 685-700.	12.8	538
8	Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings. Journal of Controlled Release, 2013, 170, 233-241.	4.8	41
9	Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis, 2013, 34, 1717-1727.	1.3	21
10	ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages. Cancer Genetics, 2013, 206, 357-373.	0.2	51
11	New drugs for children and adolescents with cancer: the need for novel development pathways. Lancet Oncology, The, 2013, 14, e117-e124.	5.1	81
12	Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nature Reviews Cancer, 2013, 13, 397-411.	12.8	632
13	Doseâ€finding designs using a novel quasiâ€continuous endpoint for multipleâ€‰toxicities. Statistics in Medicine, 2013, 32, 2728-2746.	0.8	45
14	Emerging drugs for neuroblastoma. Expert Opinion on Emerging Drugs, 2013, 18, 155-171.	1.0	22
15	Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clinical Cancer Research, 2013, 19, 6173-6182.	3.2	323
17	Report of Neuroblastoma in a Set of Monozygotic Monochorionic Twins. Pediatric Hematology and Oncology, 2013, 30, 285-287.	0.3	1
18	Current and Future Strategies for Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology, 2013, 35, 337-347.	0.3	71
19	Neuroblastoma and MYCN. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a014415-a014415.	2.9	480

#	Article	IF	Citations
20	Is the European Pediatric Medicine Regulation Working for Children and Adolescents with Cancer?. Clinical Cancer Research, 2013, 19, 1315-1325.	3.2	48
21	The ALK inhibitor ASP3026 eradicates NPM-ALK+ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model. Oncotarget, 2014, 5, 5750-5763.	0.8	29
22	Ultra-High Density SNParray in Neuroblastoma Molecular Diagnostics. Frontiers in Oncology, 2014, 4, 202.	1.3	44
23	Emergence of New ALK Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 2727-2734.	0.8	176
24	IntegratingIn SilicoPrediction Methods, Molecular Docking, and Molecular Dynamics Simulation to Predict the Impact of ALK Missense Mutations in Structural Perspective. BioMed Research International, 2014, 2014, 1-14.	0.9	40
25	Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. Blood and Lymphatic Cancer: Targets and Therapy, 0, , 69.	1.2	2
26	Drug discovery in paediatric oncology: roadblocks to progress. Nature Reviews Clinical Oncology, 2014, 11, 732-739.	12.5	28
28	A critical evaluation of PI3K inhibition in Glioblastoma and Neuroblastoma therapy. Molecular and Cellular Therapies, 2014, 2, 32.	0.2	45
29	New drug development in childhood cancer. Current Opinion in Pediatrics, 2014, 26, 37-42.	1.0	4
30	The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells. Oncogene, 2014, 33, 2236-2244.	2.6	34
31	The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line. Tumor Biology, 2014, 35, 3229-3235.	0.8	4
32	Therapeutic targets for neuroblastomas. Expert Opinion on Therapeutic Targets, 2014, 18, 277-292.	1.5	43
33	Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma. Biochemical and Biophysical Research Communications, 2014, 454, 566-571.	1.0	14
34	Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. European Journal of Medicinal Chemistry, 2014, 86, 438-448.	2.6	15
35	Advanced stage anaplastic large cell lymphoma in children and adolescents: Results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: A report from the children's oncology group. Pediatric Blood and Cancer, 2014, 61, 2236-2242.	0.8	68
36	ActualitÃ©s pharmacologiquesÂâ€“Âle crizotinib (XalkoriÂ®). Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2014, 2, 46-53.	0.1	4
37	Detection of tumor <scp>ALK</scp> status in neuroblastoma patients using peripheral blood. Cancer Medicine, 2015, 4, 540-550.	1.3	65
38	The anaplastic lymphoma kinase as an oncogene in solid tumors. Frontiers in Bioscience - Scholar, 2015, 7, 269-282.	0.8	5

#	Article	IF	Citations
39	Focal therapy of neuroblastoma using silk films to deliver kinase and chemotherapeutic agents in vivo. Acta Biomaterialia, 2015, 20, 32-38.	4.1	50
40	NewÂimmunotherapeutic strategies for the treatment of neuroblastoma. Immunotherapy, 2015, 7, 285-300.	1.0	8
41	Pediatric solid tumor genomics and developmental pliancy. Oncogene, 2015, 34, 5207-5215.	2.6	53
42	DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights. Epigenomics, 2015, 7, 1137-1153.	1.0	40
43	Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Computational Biology, 2015, 11, e1004130.	1.5	62
44	Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment. Clinical Cancer Research, 2015, 21, 3327-3339.	3.2	76
45	Intact or Broken-apart RNA. Applied Immunohistochemistry and Molecular Morphology, 2015, 23, 60-70.	0.6	3
46	Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. Cancer Research, 2015, 75, 5176-5186.	0.4	14
47	Neuroblastoma. Pediatric Clinics of North America, 2015, 62, 225-256.	0.9	328
48	Phosphoproteomics reveals ALK promote cell progress via RAS/JNK pathway in neuroblastoma. Oncotarget, 2016, 7, 75968-75980.	0.8	12
49	Primary and Metastatic Cutaneous Melanomas Express ALK Through Alternative Transcriptional Initiation. American Journal of Surgical Pathology, 2016, 40, 786-795.	2.1	41
50	Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis. Scientific Reports, 2016, 6, 19423.	1.6	42
51	ALK gene copy number gain and immunohistochemical expression status using three antibodies in neuroblastoma. Pediatric and Developmental Pathology, 0, , .	0.5	3
52	Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Clinical Cancer Research, 2016, 22, 5772-5782.	3.2	279
53	Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations. Cancer, 2016, 122, 20-33.	2.0	175
54	A Novel EGFR Extracellular Domain Mutant, EGFRÎ”768, Possesses Distinct Biological and Biochemical Properties in Neuroblastoma. Molecular Cancer Research, 2016, 14, 740-752.	1.5	8
55	Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Letters, 2016, 372, 179-186.	3.2	63
56	Equal access to innovative therapies and precision cancer care. Nature Reviews Clinical Oncology, 2016, 13, 385-393.	12.5	43

#	Article	IF	Citations
57	ALKR1275Q perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN. Oncogene, 2016, 35, 4447-4458.	2.6	19
58	Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. Analyst, The, 2016, 141, 450-460.	1.7	175
59	ALK: a tyrosine kinase target for cancer therapy. Journal of Physical Education and Sports Management, 2017, 3, a001115.	0.5	131
60	Conjugation of biogenic polyamine (putrescine) with proteinase K: Spectroscopic and theoretical insights. International Journal of Biological Macromolecules, 2017, 98, 150-158.	3.6	8
61	Advances in emerging drugs for the treatment of neuroblastoma. Expert Opinion on Emerging Drugs, 2017, 22, 63-75.	1.0	36
62	Neuroblastoma treatment in the post-genomic era. Journal of Biomedical Science, 2017, 24, 14.	2.6	82
63	Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic large cell lymphoma. Laboratory Investigation, 2017, 97, 962-970.	1.7	21
64	Genetic susceptibility to neuroblastoma. Current Opinion in Genetics and Development, 2017, 42, 81-90.	1.5	75
65	Neuroblast differentiation during development and in neuroblastoma requires KIF1BÎ²-mediated transport of TRKA. Genes and Development, 2017, 31, 1036-1053.	2.7	23
66	CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma. Nanoscale, 2017, 9, 1201-1212.	2.8	21
67	ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma. Pediatric and Developmental Pathology, 2017, 20, 133-141.	0.5	11
68	The role of anaplastic lymphoma kinase in pediatric cancers. Cancer Science, 2017, 108, 1913-1920.	1.7	31
69	Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK F1174L Drug-Resistant Neuroblastoma Preclinical Models. Translational Oncology, 2017, 10, 604-611.	1.7	12
70	Neuroblastoma: The Clinical Aspects. , 2017, , .		1
72	Kinases. , 2017, , 9-56.		1
73	Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma. Oncotarget, 2017, 8, 85234-85251.	0.8	71
74	Molecular Testing in Pediatric Cancers. , 2017, , 401-410.		0
75	A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment. Cell Death and Differentiation, 2018, 25, 2053-2070.	5.0	22

#	Article	IF	Citations
76	Characteristics of genomic alterations of lung adenocarcinoma in young neverâ€smokers. International Journal of Cancer, 2018, 143, 1696-1705.	2.3	45
77	Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma. Pediatric Blood and Cancer, 2018, 65, e27055.	0.8	28
78	Neuroblastoma. Japanese Journal of Clinical Oncology, 2018, 48, 214-241.	0.6	147
79	Alectinib is effective, safe and tolerable in an adolescent with stage IVB ALK-rearranged adenocarcinoma of the lung. Pediatric Hematology and Oncology, 2018, 35, 415-421.	0.3	3
80	Cytotoxic activity of difluoromethylornithine compared with fenretinide in neuroblastoma cell lines. Pediatric Blood and Cancer, 2018, 65, e27447.	0.8	4
81	NRP1 knockdown promotes the migration and invasion of human neuroblastoma-derived SKâ€Nâ€AS cells via the activation of Î²1Ã¯Â¿Â½integrin expression. International Journal of Oncology, 2018, 53, 159-166.	1.4	7
82	Anaplastic Lymphoma Kinase in Glioblastoma: Detection/Diagnostic Methods and Therapeutic Options. Recent Patents on Anti-Cancer Drug Discovery, 2018, 13, 209-223.	0.8	11
83	ALK in Neuroblastoma: Biological and Therapeutic Implications. Cancers, 2018, 10, 113.	1.7	105
84	Evolving paradigms for new agent development in pediatric oncology. Current Opinion in Pediatrics, 2018, 30, 10-16.	1.0	3
85	PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways. BMC Cancer, 2018, 18, 499.	1.1	31
87	OncoKids. Journal of Molecular Diagnostics, 2018, 20, 765-776.	1.2	58
88	Developing liposomal nanomedicines for treatment of patients with neuroblastoma. , 2018, , 361-411.		3
89	Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma. Clinical Cancer Research, 2019, 25, 4063-4078.	3.2	14
90	Current and Future Strategies for Treatment of Relapsed Neuroblastoma. , 2019, , 263-281.		1
91	Targeting anaplastic lymphoma kinase in neuroblastoma. Apmis, 2019, 127, 288-302.	0.9	53
92	Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment. Scientific Reports, 2019, 9, 2199.	1.6	14
93	Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma. Diagnostic Pathology, 2019, 14, 134.	0.9	12
94	Efficacy of Lorlatinib in Primary Crizotinib-Resistant Adult Neuroblastoma Harboring ALK Y1278S Mutation. JCO Precision Oncology, 2019, 3, 1-5.	1.5	5

#	Article	IF	Citations
95	ALK positively regulates MYCN activity through repression of HBP1 expression. Oncogene, 2019, 38, 2690-2705.	2.6	17
96	Efficacy of Incremental Next-Generation ALK Inhibitor Treatment in Oncogene-Addicted, ALK-Positive, TP53-Mutant NSCLC. Journal of Personalized Medicine, 2020, 10, 107.	1.1	4
97	Applications and prospects of targeted therapy for neuroblastoma. World Journal of Pediatric Surgery, 2020, 3, e000164.	0.2	2
98	Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report. Annals of Translational Medicine, 2020, 8, 1099-1099.	0.7	11
99	Pharmacokinetic Targets for Therapeutic Drug Monitoring of Small Molecule Kinase Inhibitors in Pediatric Oncology. Clinical Pharmacology and Therapeutics, 2020, 108, 494-505.	2.3	17
100	Molecular targeting therapies for neuroblastoma: Progress and challenges. Medicinal Research Reviews, 2021, 41, 961-1021.	5.0	150
101	Neuroblastomaâ€targeted nanoparticles and novel nanotechnologyâ€based treatment methods. Journal of Cellular Physiology, 2021, 236, 1751-1775.	2.0	5
102	Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lung. Histopathology, 2021, 78, 578-585.	1.6	8
103	Zebrafish as a Neuroblastoma Model: Progress Made, Promise for the Future. Cells, 2021, 10, 580.	1.8	7
104	Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, e2019132118.	3.3	3
105	Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501.	7.7	79
106	Advances in pharmacotherapy for neuroblastoma. Expert Opinion on Pharmacotherapy, 2021, 22, 2383-2404.	0.9	6
107	Downregulation of PDGFRÃŸ Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor. Translational Oncology, 2021, 14, 101099.	1.7	3
108	A New Player in Neuroblastoma: YAP and Its Role in the Neuroblastoma Microenvironment. Cancers, 2021, 13, 4650.	1.7	5
109	Nanocomplexâ€Mediated In Vivo Programming to Chimeric Antigen Receptorâ€M1 Macrophages for Cancer Therapy. Advanced Materials, 2021, 33, e2103258.	11.1	68
111	Inhibiting the Phosphoinositide 3-Kinase/AKT/Mammalian Target of Rapamycin Pathway. , 2013, , 99-132.		1
112	Intrinsic Susceptibility MRI Identifies Tumors with ALKF1174L Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma. PLoS ONE, 2014, 9, e92886.	1.1	16
113	The Role of Anaplastic Lymphoma Kinase in Human Cancers. Oncology & Hematology Review, 2013, 09, 149.	0.2	4

#	Article	IF	Citations
114	Apoptosis-related BCL2-family Members: Key Players in Chemotherapy. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 353-374.	0.9	85
115	Complete response with crizotinib in two children with chemotherapy resistant neuroblastoma. South Asian Journal of Cancer, 2017, 06, 089-090.	0.2	4
116	Neuroblastomaâ€"Telomere maintenance, deregulated signaling transduction and beyond. International Journal of Cancer, 2022, 150, 903-915.	2.3	11
118	Neuroblastoma and Ganglioneuroblastoma. , 2016, , 808-817.		0
119	Tumor Biology and Environmental Carcinogenesis. , 2016, , 19-34.		0
120	Neuroblastom. , 2018, , 419-439.		3
121	Role of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib in the Management of Neuroblastoma. Serbian Journal of Experimental and Clinical Research, 2018, .	0.2	0
122	ALK and neuroblastoma: from molecular genetics to clinics. Russian Journal of Pediatric Hematology and Oncology, 2019, 6, 54-60.	0.1	1
123	Repurposing Drugs by In Silico Methods to Target BCR Kinase Domain in Chronic Myeloid Leukemia. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3399-3406.	0.5	3
125	Targeting RAS in neuroblastoma: Is it possible?. , 2022, 236, 108054.		9
126	Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocrine Pathology, 2022, 33, 90-114.	5.2	115
127	Deciphering the Mechanism of Gilteritinib Overcoming Lorlatinib Resistance to the Double Mutant I1171N/F1174I in Anaplastic Lymphoma Kinase. Frontiers in Cell and Developmental Biology, 2021, 9, 808864.	1.8	14
128	Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets. Frontiers in Cell and Developmental Biology, 2021, 9, 811297.	1.8	3
129	Bioprinted Cancer Model of Neuroblastoma in a Renal Microenvironment as an Efficiently Applicable Drug Testing Platform. International Journal of Molecular Sciences, 2022, 23, 122.	1.8	12
130	Earlyâ€phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. Cancer, 2022, 128, 3775-3783.	2.0	2
131	Advances in the treatment of pediatric solid tumors: A 50â€year perspective. Journal of Surgical Oncology, 2022, 126, 933-942.	0.8	4
132	Advances in liquid biopsy in neuroblastoma. Fundamental Research, 2022, , .	1.6	1
133	E2F1 induced neuroblastoma cell migration and invasion via activation of CENPE/FOXM1 signaling pathway. International Journal of Neuroscience, 0, , 1-13.	0.8	1

#	Article	IF	Citations
134	Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry. Current Oncology, 2022, 29, 8222-8234.	0.9	2
135	Neuroblastom. Springer Reference Medizin, 2019, , 1-9.	0.0	0
137	Genomic ALK alterations in primary and relapsed neuroblastoma. British Journal of Cancer, 2023, 128, 1559-1571.	2.9	7
138	Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance. Drug Resistance Updates, 2023, 67, 100937.	6.5	24
141	Small round cell tumors. , 2016, , 855-894.		0
143	Molecular testing in pediatric cancers. , 2024, , 475-484.		0